Aptivus Clears FDA For HIV; B.I. To Conduct Therapeutic Monitoring Study
Executive Summary
Boehringer Ingelheim has agreed to develop a pilot study in therapeutic drug monitoring for its HIV therapy Aptivus (tipranavir)
You may also be interested in...
J&J Enters HIV Arena With Prezista; Darunavir Is Tenth Protease Inhibitor
The strength of darunavir's bond with protease may provide Johnson & Johnson/Tibotec's Prezista an advantage against other drugs in the class for treatment-experienced HIV patients
J&J Enters HIV Arena With Prezista; Darunavir Is Tenth Protease Inhibitor
The strength of darunavir's bond with protease may provide Johnson & Johnson/Tibotec's Prezista an advantage against other drugs in the class for treatment-experienced HIV patients
Aptivus Limited Part D Formulary Coverage May Reflect Approval Timing
Boehringer Ingelheim's experience with Part D placement for its HIV therapy Aptivus points to the importance of approval timing in securing formulary coverage on Medicare drug plans